Leucine Rich Repeat Serine/Threonine Protein Kinase 2 - Pipeline Review, H1 2020
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 - Pipeline Review, H1 2020
SUMMARY
According to the recently published report 'Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H1 2020'; Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 21 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes.
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system.
The report 'Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H1 2020' outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 7 and 6 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Oncology and Ophthalmology which include indications Parkinson's Disease, Neurodegenerative Diseases, Alzheimer's Disease, Crohn's Disease (Regional Enteritis), Ocular Hypertension, Open-Angle Glaucoma, Pulmonary Hypertension and Solid Tumor.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H1 2020'; Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 21 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes.
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system.
The report 'Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H1 2020' outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 7 and 6 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Oncology and Ophthalmology which include indications Parkinson's Disease, Neurodegenerative Diseases, Alzheimer's Disease, Crohn's Disease (Regional Enteritis), Ocular Hypertension, Open-Angle Glaucoma, Pulmonary Hypertension and Solid Tumor.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
- The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Overview
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Arrien Pharmaceuticals LLC
Cerevel Therapeutics LLC
D. Western Therapeutics Institute Inc
Denali Therapeutics Inc
E-scape Bio Inc
H. Lundbeck AS
Imago Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Lead Discovery Center GmbH
Merck & Co Inc
NeuBase Therapeutics Inc
Oncodesign SA
Origenis GmbH
Voronoi
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Drug Profiles
Antisense Oligonucleotides to Inhibit LRRK2 and SNCA for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARN-1104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNL-151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNL-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNE-7915 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-1337 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ION-859 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ODS-2005294 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OT-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06447475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules To Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ursodiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VN-10072 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Dormant Products
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Feb 17, 2020: Oncodesign and Servier reach a key first milestone in their strategic partnership on LRRK2 inhibitors for Parkinson’s Disease
Sep 05, 2019: Denali begins dosing Parkinson’s patients in Phase Ib trial
Sep 04, 2019: GeoVax announces publication of Lassa Fever Vaccine study results
Sep 04, 2019: BioXcel Therapeutics receives FDA Orphan Drug Designation for BXCL701 for the treatment of Acute Myeloid Leukemia (AML)
Feb 04, 2019: Liver drug trialled in Parkinsons patients as novel treatment approach
Dec 10, 2018: Denali Therapeutics announces first patient dosed in phase 1b study of DNL201 for parkinson's disease
Aug 01, 2018: Denali Therapeutics announces positive clinical results from LRRK2 inhibitor program for parkinsons disease
Apr 05, 2018: Allysta Pharmaceuticals Doses First Patient in Phase 2A Study in Glaucoma
Dec 20, 2017: Denali Therapeutics Provides Update on DNL151
Dec 20, 2017: Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson's Disease
May 23, 2017: Origenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of Neurodegenerative and Inflammatory Diseases
May 30, 2016: Oncodesign is granted new patent protecting key molecules generated from its Nanocyclix technology platform for next generation kinase inhibitors
Oct 21, 2015: Oncodesign Presents Novel LRRK2 Inhibitor Jointly Discovered with Ipsen at the 2015 Neurosciences Meeting in Chicago
Sep 09, 2014: Arrien Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued U.S. Patents No. 8,791,112 B2
Aug 16, 2012: Arrien Pharma’s ORS-1104 Advances Into Investigational New Drug Enabling Stage
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Overview
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Arrien Pharmaceuticals LLC
Cerevel Therapeutics LLC
D. Western Therapeutics Institute Inc
Denali Therapeutics Inc
E-scape Bio Inc
H. Lundbeck AS
Imago Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Lead Discovery Center GmbH
Merck & Co Inc
NeuBase Therapeutics Inc
Oncodesign SA
Origenis GmbH
Voronoi
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Drug Profiles
Antisense Oligonucleotides to Inhibit LRRK2 and SNCA for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARN-1104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNL-151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNL-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNE-7915 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-1337 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ION-859 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ODS-2005294 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OT-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06447475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules To Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ursodiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VN-10072 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Dormant Products
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Feb 17, 2020: Oncodesign and Servier reach a key first milestone in their strategic partnership on LRRK2 inhibitors for Parkinson’s Disease
Sep 05, 2019: Denali begins dosing Parkinson’s patients in Phase Ib trial
Sep 04, 2019: GeoVax announces publication of Lassa Fever Vaccine study results
Sep 04, 2019: BioXcel Therapeutics receives FDA Orphan Drug Designation for BXCL701 for the treatment of Acute Myeloid Leukemia (AML)
Feb 04, 2019: Liver drug trialled in Parkinsons patients as novel treatment approach
Dec 10, 2018: Denali Therapeutics announces first patient dosed in phase 1b study of DNL201 for parkinson's disease
Aug 01, 2018: Denali Therapeutics announces positive clinical results from LRRK2 inhibitor program for parkinsons disease
Apr 05, 2018: Allysta Pharmaceuticals Doses First Patient in Phase 2A Study in Glaucoma
Dec 20, 2017: Denali Therapeutics Provides Update on DNL151
Dec 20, 2017: Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson's Disease
May 23, 2017: Origenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of Neurodegenerative and Inflammatory Diseases
May 30, 2016: Oncodesign is granted new patent protecting key molecules generated from its Nanocyclix technology platform for next generation kinase inhibitors
Oct 21, 2015: Oncodesign Presents Novel LRRK2 Inhibitor Jointly Discovered with Ipsen at the 2015 Neurosciences Meeting in Chicago
Sep 09, 2014: Arrien Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued U.S. Patents No. 8,791,112 B2
Aug 16, 2012: Arrien Pharma’s ORS-1104 Advances Into Investigational New Drug Enabling Stage
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Arrien Pharmaceuticals LLC, H1 2020
Pipeline by Cerevel Therapeutics LLC, H1 2020
Pipeline by D. Western Therapeutics Institute Inc, H1 2020
Pipeline by Denali Therapeutics Inc, H1 2020
Pipeline by E-scape Bio Inc, H1 2020
Pipeline by H. Lundbeck AS, H1 2020
Pipeline by Imago Pharmaceuticals Inc, H1 2020
Pipeline by Ionis Pharmaceuticals Inc, H1 2020
Pipeline by Lead Discovery Center GmbH, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by NeuBase Therapeutics Inc, H1 2020
Pipeline by Oncodesign SA, H1 2020
Pipeline by Origenis GmbH, H1 2020
Pipeline by Voronoi, H1 2020
Dormant Projects, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Arrien Pharmaceuticals LLC, H1 2020
Pipeline by Cerevel Therapeutics LLC, H1 2020
Pipeline by D. Western Therapeutics Institute Inc, H1 2020
Pipeline by Denali Therapeutics Inc, H1 2020
Pipeline by E-scape Bio Inc, H1 2020
Pipeline by H. Lundbeck AS, H1 2020
Pipeline by Imago Pharmaceuticals Inc, H1 2020
Pipeline by Ionis Pharmaceuticals Inc, H1 2020
Pipeline by Lead Discovery Center GmbH, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by NeuBase Therapeutics Inc, H1 2020
Pipeline by Oncodesign SA, H1 2020
Pipeline by Origenis GmbH, H1 2020
Pipeline by Voronoi, H1 2020
Dormant Projects, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Arrien Pharmaceuticals LLC
Cerevel Therapeutics LLC
D. Western Therapeutics Institute Inc
Denali Therapeutics Inc
E-scape Bio Inc
H. Lundbeck AS
Imago Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Lead Discovery Center GmbH
Merck & Co Inc
NeuBase Therapeutics Inc
Oncodesign SA
Origenis GmbH
Voronoi
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Arrien Pharmaceuticals LLC
Cerevel Therapeutics LLC
D. Western Therapeutics Institute Inc
Denali Therapeutics Inc
E-scape Bio Inc
H. Lundbeck AS
Imago Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Lead Discovery Center GmbH
Merck & Co Inc
NeuBase Therapeutics Inc
Oncodesign SA
Origenis GmbH
Voronoi
